Injectable HIV PrEP Drug Shows Sustained High Efficacy in Extended Trials

New data from the PURPOSE 1 and PURPOSE 2 open-label extension trials confirm that twice-yearly injectable lenacapavir (Yeztugo) maintained high efficacy for HIV pre-exposure prophylaxis (PrEP) over a year. With only one new HIV infection among thousands of participants, these results reinforce its potential as a significant advancement in HIV prevention methods.